Clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: A multicenter study of the Anatolian Society of Medical Oncology (ASMO)

Basit Öğe Kaydı
dc.authoridUlas, Arife/0000-0003-2918-2592
dc.authoridSevinç, Alper/0000-0002-0499-8918
dc.authoridaksoy, asude/0000-0002-5609-9658
dc.authorwosidunal, olcun umit/IST-6684-2023
dc.authorwosidUlas, Arife/HGD-4686-2022
dc.authorwosidSevinc, Alper/KFQ-6440-2024
dc.authorwosidSevinç, Alper/KPA-4519-2024
dc.contributor.authorUnal, Olcun Umit
dc.contributor.authorOztop, Ilhan
dc.contributor.authorYasar, Nurgul
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorOzatli, Tahsin
dc.contributor.authorBozkurt, Oktay
dc.contributor.authorSevinc, Alper
dc.date.accessioned2024-06-12T11:12:53Z
dc.date.available2024-06-12T11:12:53Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackgroundSoft tissue sarcomas (STSs) are rare malignant tumors of embryogenic mesoderm origin. Primary thoracic STSs account for a small percentage of all STSs and limited published information is available. This study aimed to identify the prognostic factors for thoracic STSs and evaluate the disease's clinical outcomes. MethodsThe medical records of 109 patients with thoracic STSs who were treated between 2003 and 2013 were retrospectively reviewed. Patients' survival rates were analyzed and potential prognostic factors evaluated. ResultsThe median follow-up period was 29 months (range: 1-121 months). STSs were most frequently localized on the chest wall (n = 42; 38.5%) and lungs (n = 42; 38.5%). The most common histological types were malignant fibrous histiocytoma (n = 23; 21.1%), liposarcoma (n = 17; 15.6%), and leiomyosarcoma (n = 16; 14.7%). The median survival time of all patients was 40.3 months (95% confidence interval, 14.22-66.37 months), with one and five-year survival rates of 93.4% and 63.5%, respectively. Univariate analysis of all groups revealed that metastatic stage, unresectability, tumor diameter of >10cm, tumor location other than the chest wall, and grade 3 diseases were predictable of poor survival. However, only grade 3 diseases and tumor location other than the chest wall were confirmed by multivariate analysis as poor prognostic factors. ConclusionsPrimary thoracic STSs are rarely seen malignant tumors. Our results indicated that patients with low-grade tumors and those localized on the chest wall often experienced better survival outcomes.en_US
dc.identifier.doi10.1111/1759-7714.12150
dc.identifier.endpage90en_US
dc.identifier.issn1759-7706
dc.identifier.issn1759-7714
dc.identifier.issue1en_US
dc.identifier.pmid26273340en_US
dc.identifier.scopus2-s2.0-84920390827en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage85en_US
dc.identifier.urihttps://doi.org/10.1111/1759-7714.12150
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23346
dc.identifier.volume6en_US
dc.identifier.wosWOS:000347541900014en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofThoracic Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPrimary Thoracic Soft Tissue Sarcomaen_US
dc.subjectPrognostic Factorsen_US
dc.subjectTreatmenten_US
dc.subjectRetrospective Analysisen_US
dc.subjectChesten_US
dc.subjectEpidemiologyen_US
dc.subjectImprovementen_US
dc.subjectSurvivalen_US
dc.subjectPatternsen_US
dc.subjectTherapyen_US
dc.subjectTumorsen_US
dc.subjectTimeen_US
dc.titleClinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: A multicenter study of the Anatolian Society of Medical Oncology (ASMO)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu